SCHEMBL5138931

SCHEMBL5138931

COc1ccc2c(=O)c(O)c(-c3ccccc3OC)oc2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.74
CYP3A4 P08684 9/20 0.74
HSD17B10 Q99714 7/20 0.74
ALDH1A1 P00352 7/20 0.74
HPGD P15428 6/20 0.74
MEN1 O00255 5/20 0.74
KMT2A Q03164 5/20 0.74
TSHR P16473 3/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
ALOX15 P16050 1/20 0.73
HTT P42858 1/20 0.73
MAPT P10636 4/20 0.68
TP53 P04637 3/20 0.68
CASP1 P29466 2/20 0.68
CASP7 P55210 2/20 0.68
ABCG2 Q9UNQ0 2/20 0.68
ADORA3 P0DMS8 2/20 0.62
TUBB4A P04350 1/20 0.60
TUBB P07437 1/20 0.60
TUBA3C P0DPH7 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5433434 0.90 KDM4E (0.74) KDM4ECYP3A4HSD17B10ALDH1A1HPGD
SCHEMBL4649979 0.90 KDM4E (0.71) KDM4ECYP3A4HSD17B10ALDH1A1HPGD
SCHEMBL4649997 0.89 ABCG2 (0.64) KDM4ECYP3A4HSD17B10ALDH1A1HPGD
SCHEMBL4649481 0.85 KDM4E (1.00) KDM4ECYP3A4HSD17B10ALDH1A1HPGD
SCHEMBL31675993 0.85 KDM4E (1.00) KDM4ECYP3A4HSD17B10ALDH1A1HPGD
SCHEMBL4650094 0.85 KDM4E (0.81) KDM4ECYP3A4HSD17B10ALDH1A1HPGD
SCHEMBL17079654 0.85 KDM4E (1.00) KDM4ECYP3A4HSD17B10ALDH1A1HPGD
SCHEMBL15676588 0.84 KDM4E (0.85) KDM4ECYP3A4HSD17B10ALDH1A1HPGD
SCHEMBL4650060 0.84 KDM4E (0.85) KDM4ECYP3A4HSD17B10ALDH1A1HPGD
SCHEMBL28183163 0.82 KDM4E (0.70) KDM4ECYP3A4HSD17B10ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 KDM4E 1065/4885CYP3A4 17/4885HSD17B10 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.